SLC5A2 and neoplasm: SGLT2 inhibitors selectively inhibit glucose uptake by SGLT2-expressing human liver cancer cells, such as Huh7 and HepG2 cells, reducing intracellular adenosine triphosphate (ATP) levels, inducing apoptosis, and indirectly suppressing tumor angiogenesis [64].